US stock · Healthcare sector · Medical Devices
Company Logo

Abbott Laboratories

ABTNYSE

101.69

USD
+0.91
(+0.90%)
Market Closed
25.39P/E
22Forward P/E
1.20P/E to S&P500
176.834BMarket CAP
1.94%Div Yield
Upcoming Earnings
18 Jul-24 Jul
Shares Short
5/15/23
12.95M
Short % of Float
0.75%
Short % of Shares Outs.
0.74%
% Held by Insiders
0.55%
% Held by Institutions
76.06%
Beta
0.67
PEG Ratio
-8.48
52w. high/low
115.69/93.25
Avg. Daily Volume
4.81M
Return %
Stock
S&P 500
1 year
(15.14)
(9.05)
3 years
24.97
50.26
5 years
55.03
38.50
Scale: |
High
Low
29.31
21.95
27.54
19.80
27.25
21.39
27.08
21.62
34.77
25.89
38.81
31.64
46.50
35.65
51.74
39.00
45.79
36.00
57.77
38.34
74.92
55.58
89.24
65.50
115.14
61.61
142.60
105.36
139.83
93.25
115.69
96.39
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
16.79
19.13
19.89
22.73
24.74
25.29
14.11
13.43
13.86
14.16
15.71
17.42
18.10
19.54
24.32
24.65
Earnings per share
2.34
3.16
3.72
2.99
3.01
3.78
1.66
1.51
3.00
0.95
0.27
1.35
2.09
2.54
3.99
3.91
FCF per share
2.29
3.92
4.00
4.99
4.76
4.77
1.41
1.72
1.26
1.41
2.54
2.79
2.55
3.23
4.88
4.41
Dividends per share
1.27
1.41
1.56
1.73
1.87
2.02
0.57
0.89
0.98
1.04
1.06
1.12
1.29
1.45
1.81
1.87
CAPEX per share
1.07
0.83
0.70
0.66
0.95
1.14
0.74
0.71
0.75
0.76
0.65
0.79
0.93
1.23
1.06
1.00
Book Value per sh.
11.52
11.32
14.78
14.47
15.56
16.95
16.26
14.27
14.40
13.94
17.72
17.39
17.64
18.51
20.21
20.71
Comm.Shares outs.
1,543
1,544
1,546
1,547
1,570
1,577
1,548
1,508
1,473
1,473
1,744
1,756
1,763
1,771
1,771
1,771
Avg. annual P/E ratio
11.2
8.3
6.2
8.1
8.1
7.9
21.3
27.0
15.3
42.4
177.2
47.6
38.3
37.7
30.5
28.5
P/E to S&P500
0.6
0.4
0.1
0.4
0.5
0.5
1.3
1.5
0.8
1.9
7.5
1.9
1.6
1.0
1.0
1.3
Avg. annual div. yield
4.9%
5.4%
6.7%
7.1%
7.7%
6.7%
1.6%
2.2%
2.1%
2.6%
2.2%
1.8%
1.6%
1.5%
1.5%
1.7%
Revenue (m)
25,914
29,528
30,765
35,167
38,851
39,874
21,848
20,247
20,405
20,853
27,390
30,578
31,904
34,608
43,075
43,653
Operating margin
17.7%
19.3%
20.3%
17.3%
14.8%
20.3%
12.0%
12.8%
14.1%
15.3%
6.3%
11.9%
14.2%
15.5%
19.6%
19.2%
Depreciation (m)
1,855
1,839
2,090
2,624
3,044
2,783
1,719
1,548
1,472
1,353
3,021
3,278
3,014
3,327
3,538
2,013
Net profit (m)
3,606
4,881
5,746
4,626
4,728
5,963
2,576
2,284
4,423
1,400
477
2,368
3,687
4,495
7,071
6,933
Income tax rate
19.3%
19.2%
20.1%
19.0%
9.0%
4.8%
5.5%
31.7%
18.1%
24.8%
84.2%
18.8%
9.6%
10.0%
13.9%
16.5%
Net profit margin
13.9%
16.5%
18.7%
13.2%
12.2%
15.0%
11.8%
11.3%
21.7%
6.7%
1.7%
7.7%
11.6%
13.0%
16.4%
15.9%
Working capital (m)
4,939
5,451
10,264
5,055
8,289
18,042
9,740
4,729
4,969
20,116
11,235
5,620
4,804
8,534
11,134
9,735
Long-term debt (m)
9,488
8,713
11,266
12,524
12,040
18,085
3,388
3,408
5,871
20,681
27,210
19,359
16,661
19,429
18,252
22,044
Equity (m)
17,779
17,480
22,856
22,388
24,440
26,721
25,171
21,526
21,211
20,538
30,897
30,524
31,088
32,784
35,802
36,686
ROIC
11.8%
17.1%
15.7%
12.0%
11.7%
12.1%
8.1%
7.2%
13.2%
3.6%
0.8%
5.2%
7.6%
8.2%
12.2%
33.8%
Return on capital
11.3%
15.4%
14.7%
10.6%
9.5%
10.2%
6.7%
7.8%
12.6%
4.2%
4.3%
5.6%
7.0%
7.7%
11.7%
23.5%
Return on equity
20.3%
27.9%
25.1%
20.7%
19.3%
22.3%
10.2%
10.6%
20.9%
6.8%
1.5%
7.8%
11.9%
13.7%
19.8%
18.9%
Plowback ratio
45.7%
55.5%
58.0%
42.3%
37.9%
46.6%
65.8%
41.2%
67.4%
(9.9)%
(287.6)%
16.6%
38.4%
43.0%
54.7%
52.3%
Div.&Repurch./FCF
50.1%
53.8%
52.4%
45.8%
40.3%
73.8%
114.1%
136.1%
198.3%
99.0%
60.3%
45.1%
66.4%
51.8%
63.6%
91.0%
Capital Structure
17 Feb · 2023 | Q4
All numbers in millions
Total liabilities
$ 219
Total assets
$ 74,438
Long-term debt
$ 22,044
Cash and equiv.
$ 9,882
Goodwill
$ 22,799
Retained earnings
$ 41,770
Common stock
1,744
Enterprise Value
$ 188,996
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
7,148
10,249
10,170
Receivables
6,414
6,487
6,218
Inventory
5,012
5,157
6,173
Other
1,867
5,307
5,707
Current assets
20,441
24,239
25,224
Acc. Payable
3,946
4,408
4,607
Debt due
220
754
2,251
Other
7,741
7,943
8,631
Current liabilities
11,907
13,105
15,489
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
1.34%
9.65%
8.58%
Cash flow
(9.76)%
15.07%
20.75%
Earnings
(1.95)%
33.24%
53.05%
Dividends
3.34%
14.05%
16.60%
Book value
2.47%
4.74%
5.45%
Insider Trading
Type
Shares
Date
Woodgrift Randel William
Sale
1,032
03/01/23
Wainer Andrea F
Sale
679
03/01/23
Watkin Jared
Sale
1,198
03/01/23
Tyler Julie L.
Sale
525
03/01/23
Salvadori Daniel Gesua Sive
Sale
1,085
03/01/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
7,726
7,328
8,853
10,701
34,608
2021
10,456
10,223
10,928
11,468
43,075
2022
11,895
11,257
10,410
10,091
43,653
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.32
0.30
0.70
1.22
2.54
2021
1.01
0.67
1.19
1.12
3.99
2022
1.38
1.14
0.81
0.58
3.91
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.36
0.36
0.36
0.36
1.45
2021
0.45
0.45
0.45
0.45
1.81
2022
0.47
0.47
0.47
0.46
1.87
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Robert B. Ford
Full-time employees:
113,000
City:
North Chicago
Address:
100 Abbott Park Road
IPO:
Mar 1, 1937
Website:
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Recent News
· 20 Jan, 2023 · The Wall Street Journal
· 20 Jul, 2022 · The Wall Street Journal
· 10 Jul, 2022 · The Wall Street Journal
· 16 Jun, 2022 · The Wall Street Journal
· 8 Jun, 2022 · The Wall Street Journal
· 4 Jun, 2022 · The Wall Street Journal
· 25 May, 2022 · The Wall Street Journal
· 24 May, 2022 · The Wall Street Journal
· 17 May, 2022 · The Wall Street Journal
· 12 May, 2022 · The Wall Street Journal
· 11 May, 2022 · The Wall Street Journal
· 18 Apr, 2022 · The Wall Street Journal
· 1 Mar, 2022 · The Wall Street Journal
· 26 Jan, 2022 · The Wall Street Journal